TY - JOUR
T1 - PARP Inhibitors in First-Line Therapy of Ovarian Cancer
T2 - Are There Any Doubts?
AU - Franzese, Elisena
AU - Diana, Anna
AU - Centonze, Sara
AU - Pignata, Sandro
AU - De Vita, Ferdinando
AU - Ciardiello, Fortunato
AU - Orditura, Michele
PY - 2020/6/12
Y1 - 2020/6/12
N2 - The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors (olaparib, niraparib, veliparib) in first-line therapy of OC have been presented. For the first time, these studies evaluated the efficacy of PARP inhibitors in this setting and the relative predictive biomarkers for patients' selection. The use of a PARP inhibitor is related with prolonged progression free survival (PFS) in the whole population of NADOC, although the magnitude of benefit varies widely among subgroups, highlighting the need to identify specific biological subtypes into clinical practice. In this minireview, we discuss the updated data available from clinical studies in this scenario.
AB - The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors (olaparib, niraparib, veliparib) in first-line therapy of OC have been presented. For the first time, these studies evaluated the efficacy of PARP inhibitors in this setting and the relative predictive biomarkers for patients' selection. The use of a PARP inhibitor is related with prolonged progression free survival (PFS) in the whole population of NADOC, although the magnitude of benefit varies widely among subgroups, highlighting the need to identify specific biological subtypes into clinical practice. In this minireview, we discuss the updated data available from clinical studies in this scenario.
KW - BRCA 1/2 mutation carriers
KW - first line
KW - homologous recombination
KW - ovarian cancer
KW - PARP inhibitor (PARPi)
UR - http://www.scopus.com/inward/record.url?scp=85087035647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087035647&partnerID=8YFLogxK
U2 - 10.3389/fonc.2020.00782
DO - 10.3389/fonc.2020.00782
M3 - Review article
AN - SCOPUS:85087035647
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
SN - 2234-943X
M1 - 782
ER -